Axcella Therapeutics (AXLA) Misses Q4 EPS by 2c

Axcella Therapeutics (NASDAQ: AXLA) reported Q4 EPS of ($0.46), $0.02 worse than the analyst estimate of ($0.44).

For earnings history and earnings-related data on Axcella Therapeutics (AXLA) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Star Equity Holdings (STRR) Misses Q2 EPS by 8c
• HeartCore Enterprises, Inc. (HTCR) Misses Q2 EPS by 185c